Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations

Journal of Clinical Oncology

Volumn 34, Issue 18, 2016, Pages 2165-2171

  Choudhury, Noura J ^a   Campanile, Alexa ^a   Antic, Tatjana ^a   Yap, Kai Lee ^a   Fitzpatrick, Carrie A ^a   Wade, James L ^b   Karrison, Theodore ^a   Stadler, Walter M ^a   Nakamura, Yusuke ^a   O'Donnell, Peter H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Decatur Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG SENSITIVITY; FATIGUE; FEMALE; GENE AMPLIFICATION; HEART EJECTION FRACTION; HUMAN; LIVER METASTASIS; MALE; METASTATIC PLATINUM REFRACTORY UROTHELIAL CARCINOMA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SOMATIC MUTATION; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; UROLOGIC NEOPLASMS; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84973629991     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.66.3047     Document Type: Article

References (52)

1. Society AC: Cancer Facts and Figures 2015. Atlanta, GA, American Cancer Society, 2015
2. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-562, 2014
3. Hussain MH, Wood DP, Bajorin DF, et al: Bladder cancer: Narrowing the gap between evidence and practice. J Clin Oncol 27:5680-5684, 2009
4. Mooso BA, Vinall RL, Mudryj M, et al: The role of EGFR family inhibitors in muscle invasive bladder cancer: A review of clinical data and molecular evidence. J Urol 193:19-29, 2015
5. Chow NH, Chan SH, Tzai TS, et al: Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 7:1957-1962, 2001
6. van Kessel KE, Zuiverloon TC, Alberts AR, et al: Targeted therapies in bladder cancer: An overview of in vivo research. Nat Rev Urol 12:681-694, 2015
7. Baselga J, Swain SM: Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463-475, 2009
8. Neal DE, Marsh C, Bennett MK, et al: Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours. Lancet 325:366-368, 1985
9. Chow NH, Liu HS, Lee EI, et al: Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 17:1293-1296, 1997
10. Neal DE, Sharples L, Smith K, et al: The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65:1619-1625, 1990
11. Nguyen PL, Swanson PE, Jaszcz W, et al: Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 101:166-176, 1994
12. Fleischmann A, Rotzer D, Seiler R, et al: Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 60:350-357, 2011
13. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:315 -322, 2014
14. Iyer G, Al-Ahmadie H, Schultz N, et al: Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 31:3133-3140, 2013
15. Pruthi RS, Nielsen M, Heathcote S, et al: A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Clinical and pathological results. BJU Int 106:349-354, 2010
16. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, et al: Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 105:317-321, 2010
17. Philips GK, Halabi S, Sanford BL, et al: A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: Results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 20:1074-1079, 2009
18. Hussain MH, MacVicar GR, Petrylak DP, et al: Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25:2218-2224, 2007
19. Wülfing C, Machiels JP, Richel DJ, et al: A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115:2881-2890, 2009
20. Afatinib. Silver Spring, MD, U.S. Food and Drug Administration, 2013
21. Machiels JP, Haddad RI, Fayette J, et al: Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinumbased therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial. Lancet Oncol 16:583-594, 2015
22. Sonpavde G, Pond GR, Fougeray R, et al: Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: A retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 63:717-723, 2013
23. Yap KL, Kiyotani K, Tamura K, et al: Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin Cancer Res 20:6605-6617, 2014
24. Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013
25. Lee YS, Cho YS, Lee GK, et al: Genomic profile analysis of diffuse-type gastric cancers. Genome Biol 15:R55, 2014
26. Li M, Zhang Z, Li X, et al: Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet 46:872-876, 2014
27. Mouradov D, Sloggett C, Jorissen RN, et al: Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res 74:3238-3247, 2014
28. Bentivegna S, Zheng J, Namsaraev E, et al: Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD). Hum Mutat 29:441-450, 2008
29. Wang K, Yuen ST, Xu J, et al: Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 46:573-582, 2014
30. Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075, 2008
31. Blehm KN, Spiess PE, Bondaruk JE, et al: Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: Implications for therapy. Clin Cancer Res 12:4671-4677, 2006
32. Bellmunt J, Théodore C, Demkov T, et al: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454-4461, 2009
33. Plimack E, Gupta S, Bellmunt J, et al: LBA23 - A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced urothelial tract cancer. Ann Oncol 25: 2014 (suppl 4; abstr 1093)
34. Chaux A, Cohen JS, Schultz L, et al: High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: A study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol 43:1590-1595, 2012
35. Gala K, Chandarlapaty S: Molecular pathways: HER3 targeted therapy. Clin Cancer Res 20: 1410-1416, 2014
36. Lee-Hoeflich ST, Crocker L, Yao E, et al: A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res 68: 5878-5887, 2008
37. Baselga J, Cortés J, Kim SB, etal: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
38. Sergina NV, Rausch M, Wang D, et al: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441, 2007
39. Kruser TJ, Wheeler DL: Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316:1083-1100, 2010
40. Junttila TT, Akita RW, Parsons K, et al: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440, 2009
41. Krüger S, Weitsch G, Büttner H, et al: Over-expression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: Relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 21:981-987, 2002
42. Coombs LM, Pigott DA, Sweeney E, et al: Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 63:601-608, 1991
43. Caner V, Turk NS, Duzcan F, et al: No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 14:261-266, 2008
44. Bellmunt J, Werner L, Bamias A, et al: HER2 as a target in invasive urothelial carcinoma. Cancer Med 4:844-852, 2015
45. Jimenez RE, Hussain M, Bianco FJ Jr, et al: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7:2440-2447, 2001
46. Krüger S, Weitsch G, Büttner H, et al: HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications. Int J Cancer 102:514-518, 2002
47. Grivas PD, Day M, Hussain M: Urothelial carcinomas: A focus on human epidermal receptors signaling. Am J Transl Res 3:362-373, 2011
48. Ocana A, Vera-Badillo F, Seruga B, et al: HER3 overexpression and survival in solid tumors: A metaanalysis. J Natl Cancer Inst 105:266-273, 2013
49. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012
50. Xue R, Li R, Guo H, et al: Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma. Gastroenterology doi:S0016-5085(15)01861-2
51. Guancial EA, Werner L, Bellmunt J, et al: FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med 3: 835-844, 2014
52. Gainor JF, Shaw AT: Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 31:3987-3996, 2013